Praveen Kumar Marimuthu: Preliminary Results with the Combo of Chemo, OMT and Low-Dose Nivo in Unresectable Oral Cancers
Praveen Kumar Marimuthu, DM Resident in Medical Oncology at the Christian Medical College and Hospital, reshared a post by Ashish Singh, Professor and Medical Oncologist at Christian Medical College Vellore, on X, adding:
“We had reported encouraging preliminary results with the combo of chemo, OMT and Low-Dose Nivo in the Frontline setting for unresectable oral cancers at ESMO24.
Abstract Annals of Oncology. Final results will be out later this year.”
Quoting Ashish Singh‘s post:
“Amazing collective effort from the group.
Congratulations research which matters and changes practice on the ground. Enough evidence to indicate that OMCT backbone with immunotherapy must be studied in a frontline trial.”
862P Neoadjuvant chemo-immunotherapy using carboplatin, nab-paclitaxel, oral metronomic therapy and low dose nivolumab for “borderline resectable” oral cavity carcinoma: A prospective phase II single-arm trial (NeoLOCUS).
Authors: P.K. Marimuthu, A.J. Tirkey, S. Sahu, A.O. John, J.T. Georgy, D.B. Thumaty, J. Riju, V. Konduru, M. Agrawal, B.K. Sasidharan, M. Mathew, S.K. Sidhique, A. Joel, R.T. Chacko, P. Jambunathan, K. Harikrishna, M. Thomas, J. Rani, and A. Singh.
You can read the full article on Journal of Annals of Oncology.
More posts featuring Praveen Kumar Marimuthu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023